PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 3141170-4 1988 Strains producing TEM-2 and CEP-1 were resistant to LY163892, cefaclor and cephalexin. loracarbef 52-60 RASD family member 2 Homo sapiens 18-23 8375126-2 1993 Data analyzed from subjects with various degrees of renal dysfunction who were given single oral doses of loracarbef indicated a linear relationship between creatinine clearance (CLCR) and plasma clearance [CLP (L/hr) = 0.106.CLCR (ml/min/1.73 m2)]. loracarbef 106-116 CD59 molecule (CD59 blood group) Homo sapiens 235-240 3141170-2 1988 OXA-2, TEM-1, TEM-2, PSE-1, CEP-1, CARB-3 and SHV-1 beta-lactamases showed similar activity against LY163892 and cefaclor, whereas OXA-1 hydrolyzed the latter more rapidly. loracarbef 100-108 CD248 molecule Homo sapiens 7-12 3141170-2 1988 OXA-2, TEM-1, TEM-2, PSE-1, CEP-1, CARB-3 and SHV-1 beta-lactamases showed similar activity against LY163892 and cefaclor, whereas OXA-1 hydrolyzed the latter more rapidly. loracarbef 100-108 RASD family member 2 Homo sapiens 14-19 3141170-2 1988 OXA-2, TEM-1, TEM-2, PSE-1, CEP-1, CARB-3 and SHV-1 beta-lactamases showed similar activity against LY163892 and cefaclor, whereas OXA-1 hydrolyzed the latter more rapidly. loracarbef 100-108 importin 5 Homo sapiens 21-26 8447851-1 1993 Loracarbef ((6R, 7S)-7-[(R)-2-amino-2-phenyl-acetamido]-3-chloro-8-oxo-1- azabicyclo [4.2.0]oct-2-ene-2-carboxylic acid, monohydrate, LY 163892, CAS 121961-22-6) is a carbacephem antibiotic targeted for use in the treatment of infectious disease. loracarbef 0-10 BCAR1 scaffold protein, Cas family member Homo sapiens 145-148 3141170-2 1988 OXA-2, TEM-1, TEM-2, PSE-1, CEP-1, CARB-3 and SHV-1 beta-lactamases showed similar activity against LY163892 and cefaclor, whereas OXA-1 hydrolyzed the latter more rapidly. loracarbef 100-108 centriolin Homo sapiens 28-33 3141170-4 1988 Strains producing TEM-2 and CEP-1 were resistant to LY163892, cefaclor and cephalexin. loracarbef 52-60 centriolin Homo sapiens 28-33 10837442-6 2000 Susceptibilities to loracarbef (P < 0.001) and cefprozil were also reduced in the presence of ROB-1 while the activities of cefuroxime, cefotaxime, cefixime and imipenem were similar in both TEM- and ROB-1-positive solates. loracarbef 20-30 Rob-1 Haemophilus influenzae 97-102 10837442-6 2000 Susceptibilities to loracarbef (P < 0.001) and cefprozil were also reduced in the presence of ROB-1 while the activities of cefuroxime, cefotaxime, cefixime and imipenem were similar in both TEM- and ROB-1-positive solates. loracarbef 20-30 Rob-1 Haemophilus influenzae 203-208 10917380-2 2000 CASE SUMMARY: A 54-year-old Native American woman was admitted for pneumonia after completing a 10-day course of loracarbef 200 mg po bid. loracarbef 113-123 BH3 interacting domain death agonist Homo sapiens 134-137